Mediclarum
Medicine guide

Eltrombopag

75 mg · Tablet

  • Prescription only
  • Thrombopoietin Receptor Agonist
Active substance
Eltrombopag Olamine
Made by
Hikma Pharmaceuticals USA Inc.

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

This information is not included in the verified source. Open the official leaflet

How it works

From the US prescribing label for the same active substance (Eltrombopag olamine). It describes the substance, not this exact product.

Eltrombopag is a TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor (also known as cMpl) and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes leading to increased platelet production.

Peak level after2–6 h
Half-life21–32 h
Mostly cleared after≈ 6 daysfive half-lives — our arithmetic
PeakHalf gone6 days0
The shape is a standard model drawn from the two times above, not a measurement. How fast a medicine acts and wears off also depends on the dose, the form and the person.
How the body breaks it down

Absorbed eltrombopag is extensively metabolized, predominantly through pathways, including cleavage, oxidation, and conjugation with glucuronic acid, glutathione, or cysteine.

With food

Effect of Food A standard high-fat breakfast (876 calories, 52 g fat, 71 g carbohydrate, 34 g protein, and 427 mg calcium) significantly decreased plasma eltrombopag AUC 0-INF by approximately 59% and C max by 65% and delayed T max by 1 hour.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-06-30

Safety of the active substance

From the US prescribing label for the same active substance (Eltrombopag olamine). It describes the substance, not this exact product.

Serious warning

WARNING: RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C and RISK OF HEPATOTOXICITY.

Most common side effects

The most common adverse reactions (≥ 20% in any indication) were: anemia, nausea, pyrexia, alanine aminotransferase increased, cough, fatigue, headache, and diarrhea.

Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

FranceNo exact match for this strength and form

Every strength and form (28)

Details

Made byHikma Pharmaceuticals USA Inc.
Active substanceEltrombopag Olamine
Strength75 mg
FormTablet
RouteOral
Packs30 TABLET in 1 BOTTLE
NDC0054-0965

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page

Other strengths and forms

34 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

Eltrombopag12.5 mgPrescription onlyTablet Hikma Pharmaceuticals USA Inc. · Eltrombopag OlamineEltrombopag25 mgPrescription onlyTablet Hikma Pharmaceuticals USA Inc. · Eltrombopag OlamineEltrombopag50 mgPrescription onlyTablet Hikma Pharmaceuticals USA Inc. · Eltrombopag OlamineEltrombopag12.5 mgPrescription onlyPowder, for Suspension Camber Pharmaceuticals, Inc. · Eltrombopag OlamineEltrombopag25 mgPrescription onlyPowder, for Suspension Camber Pharmaceuticals, Inc. · Eltrombopag OlamineEltrombopag25 mgPrescription onlyTablet, Film Coated Biocon Pharma Inc. · Eltrombopag Olamine

See every product with Eltrombopag Olamine